Thanks to private funding, 100% of every dollar donated to The Lustgarten Foundation goes directly to pancreatic cancer research.

Research Awards Listing

Research follows dollars, and The Lustgarten Foundation believes that increasing funds for pancreatic cancer research will translate into enhanced patient care, and ultimately, a cure.

The Lustgarten Foundation firmly believes that increasing funds for pancreatic cancer research is the surest path to improved patient care and eventually, to a cure. To date, we have committed more than $120 million to providing the best and brightest minds with the resources to pursue the study and eradication of the disease.

View Award Listings by Year

2015 | 2014 |  2013  |  2012  |  2011  |  2010  | 2009  |  2008  | 2007  |  2006  |  2005  |  2004  |  2003  |  2002  |  2001  |  2000-1998

2014 Research Grants

David Tuveson, M.D., Ph.D.
Pancreatic Cancer Biology and Therapy
Cold Spring Harbor Laboratory

Douglas Fearon, M.D.
Immunological Control of Pancreatic Cancer
Cold Spring Harbor Laboratory

Charles Fuchs, M.D.
Mandar Muzumdar, M.D.
Obesity-Driven PDAC -- A Comprehensive Study to Define New Targets for Prevention and Therapy
Dana-Farber Cancer Institute 
Massachusetts Institute of Technology

Robert Mayer, M.D.
Brian Wolpin, M.D., M.P.H.
Matthew Vander Heiden, M.D., Ph.D.
Metabolism and Pancreatic Cancer Pathogenesis: A Multi-Institutional Approach to Define Novel Screening Modalities and Treatments for Pancreatic Cancer
Dana-Farber Cancer Institute

Alison Klein, M.D.
Identification of Individuals at High Risk for Pancreatic Cancer
Johns Hopkins University

Bert Vogelstein, M.D.
Implying Cancer Genetics to Improve the Diagnosis, Prognosis and Treatment of Patients with Pancreatic Cancer
Johns Hopkins University

Hidde Ploegh, Ph.D.
Non-Invasive Monitoring of Inflammation and the Immune Response Against Pancreatic Cancer
Massachusetts Institute of Technology

Tyler Jacks, Ph.D.
Genome-Wide CRISPR-based Screens to Identify Unique Vulnerabilities in K-ras Dependent Pancreatic Cancer Cells
Massachusetts Institute of Technology

Scott Lowe, Ph.D.
Target Identification and Validation in Pancreatic Ductal Adenocarcinoma
Memorial Sloan Kettering Cancer Center

Steve Leach, M.D.
Large-Scale, Systemic Evaluation of Combination Therapies for Pancreatic Ductal Adenocarcinoma
Memorial Sloan Kettering Cancer Center

Ron Evans, Ph.D.
Curing Pancreatic Cancer Through Epigentic Reprogramming
Salk Institute for Biological Studies

Julien Sage, Ph.D 
Protein Methyltransferase Signaling -- Discovery of Novel Therapeutic Targets in Pancreatic Cancer
Stanford University

Frank McCormick, Ph.D
New Ways of Treating Pancreatic Cancer Based on Reversing K-Ras Mediated Stemness
University of California, San Francisco

Diane Simeone, M.D.
Personalized Theraputics Using a Novel Circultaing Tumor Cell Ex Vivo Expansion Model
University of Michigan

Channing Der, Ph.D.
Identification and Validation of RAF Inhibitor-based combination K-Ras Targeted Therapies
University of North Carolina

Stephen Fesik, Ph.D.
Discovery of Small Molecules that Target the RAS/SOS Complex for the Treatment of Pancreatic Cancer
Vanderbilt University

Lewis Cantley, Ph.D.
Targeting PIP4K2A/B for Pancreatic Cancer Therapy
Weill Cornell Medical Center

415 Crossways Park Drive, Suite D, Woodbury, NY 11797
Toll Free: 1-866-789-1000 P: 516-737-1550 F: 516-584-6265


2015 website development and design sponsored by Celgene